GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE)

Heloisa Orsini1, Leandro P Araujo1, Juliana T Maricato1

  • 1Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.

Insights

The general control nonrepressible 2 (GCN2) kinase is crucial for the remission phase in experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis model. GCN2 activation by indoleamine 2,3-dioxygenase (IDO) promotes regulatory T cell expansion and disease recovery.

Area of Science:

  • Neuroimmunology
  • Immunology
  • Molecular Biology

Background:

  • Experimental autoimmune encephalomyelitis (EAE) is a key model for studying multiple sclerosis (MS) pathogenesis.
  • While Th1/Th17 cells drive EAE, disease remission involves regulatory T cells (Treg) and anti-inflammatory cytokines, though mechanisms remain unclear.

Purpose of the Study:

  • To investigate the role of the general control nonrepressible 2 (GCN2) kinase, a regulator of amino-acid starvation response, in the EAE remission phase.
  • To explore the link between GCN2, indoleamine 2,3-dioxygenase (IDO) activity, and the development of immune tolerance during EAE recovery.

Main Methods:

  • Comparison of EAE development and remission in wild-type (WT) and GCN2 knock-out (GCN2 KO) C57BL/6 mice immunized with MOG35-55 peptide.
  • Analysis of central nervous system (CNS) inflammation, T cell populations (Th1, Th17, Treg), and expression of IDO and plasmacytoid dendritic cells (pDCs).

Main Results:

  • GCN2 KO mice failed to enter the remission phase of EAE, exhibiting sustained CNS inflammation and higher effector T cell (Th1/Th17) levels.
  • WT mice showed increased IDO expression and pDC frequency at peak EAE, correlating with higher Treg cell presence and disease remission.
  • GCN2 KO mice had significantly lower Treg cell frequencies in the CNS compared to WT mice.

Conclusions:

  • GCN2 kinase plays a critical role in mediating the remission phase of EAE.
  • IDO activity, sensed by GCN2, appears to be a key trigger for EAE remission by promoting Treg cell expansion and suppressing effector T cell responses within the CNS.

Related Concept Videos